REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/20/2026
Back to search
Official data from USPTO
MODAG
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079292215Class
1, 5, 10, 42, 44
Filing
79292215
Registration
6422358
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
07/20/2026
Trademark type
Combined
Nice classes
1, 5, 10, 42, 44
Filing date
01/31/2020
Registration date
07/20/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/20/2021
Last transaction
07/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
27
Owner location
DE
Examiner
CHUO, EMILY M
Law office
L10
Current location
TMEG LAW OFFICE 101
Mark description
The mark consists of the wording "MODAG" in a stylized font where the letters "M", "D", "A" and "G" are in dark blue, the letter "O" is grey, and the letters "O" and "G" encircle a green dot.
Holders and representatives
Holders
MODAG GmbH
Representatives
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell, & Berkowitz, PC
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical substanceschemical materialschemical compositions and chemical preparationsall of the foregoing for use in science
Class 5
Pharmaceutical drugs and medicines for the treatment of the nervous system and for the treatment of diseases characterized by pathological protein aggregation; diagnostic preparations for medical purposes
Class 10
Medical apparatus and instruments for monitoring molecular biomarkers of neurodegenerative diseases and diseases characterized by pathological protein aggregation such as pathologically modified and/or pathologically aggregated proteins and parts and fittings therefor; Medical diagnostic apparatus for testing molecular biomarkers of neurodegenerative diseases and diseases characterized by pathological protein aggregation such as pathologically modified and/or pathologically aggregated proteins and parts and fittings therefor
Class 42
Scientific and technological servicesresearch and design in the field of neurodegenerative diseases and diseases characterized by pathological protein aggregation; industrial analysis and research services in the field of neurodegenerative diseases and diseases characterized by pathological protein aggregation; biological research; research and development of new products for others; Conducting clinical trials for others in the field of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation; Scientific laboratory services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; testing of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; research and development of vaccines and medicines; pharmaceutical drug development services
Class 44
Medical services in the field of diseases characterized by pathological protein aggregation; Medical diagnosis of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation; medical services in the field of neurodegenerative diseases; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosisprognosis and treatment of neurodegenerative diseases and diseases characterized by pathological protein aggregation; providing medical data and information in the field of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation to healthcare professionals; rental of medical apparatus and equipmentfittings therefor
Publications
History of USPTO decisions and trademark events.
31 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/11/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/26/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/26/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/26/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/26/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/26/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/19/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/01/2021
FIMP
FINAL DISPOSITION PROCESSED
12/01/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/20/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/20/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/04/2021
PUBO
PUBLISHED FOR OPPOSITION
05/04/2021
GPNX
NOTIFICATION PROCESSED BY IB
05/02/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/14/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/14/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/14/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/31/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/23/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/22/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/22/2021
RFNT
REFUSAL PROCESSED BY IB
10/19/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/25/2020
RFRR
REFUSAL PROCESSED BY MPU
09/25/2020
MAFR
APPLICATION FILING RECEIPT MAILED
08/25/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/22/2020
CNRT
NON-FINAL ACTION WRITTEN
08/21/2020
DOCK
ASSIGNED TO EXAMINER
08/21/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/21/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/20/2020
Continuous trademark protection
Get notified about every new filing that threatens MODAG or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.